Progress of single-cell sequencing technology in immunotherapy for tuberculosis

Area of Science:

• Immunology
• Infectious Diseases
• Genomics

Background:

• Tuberculosis (TB) is a leading infectious cause of death globally, with increasing drug-resistant cases and limited interventions.
• Early diagnosis and treatment are crucial for pulmonary TB patients, but current methods face challenges.
• The immune system's role in TB pathogenesis is complex, necessitating advanced analytical approaches.

Purpose of the Study:

• To provide a critical overview of immunological mechanisms in TB.
• To review current advancements in TB immunotherapy and single-cell sequencing (SCS) technology.
• To highlight the clinical implications and future research directions for SCS in TB immunotherapy.

Main Methods:

• Literature review focusing on recent studies in TB immunology, immunotherapy, and SCS.
• Analysis of SCS technology's application in understanding immune cell dynamics in TB.
• Examination of novel therapeutic strategies, including vaccines and host-directed therapies.

Main Results:

• Immunotherapy, including vaccines like M72/AS01E, shows promise in TB prevention and treatment.
• Host-directed therapies, such as nano-based drug delivery, enhance treatment outcomes.
• SCS technology offers deep insights into immune cell function, distribution, and communication in TB, aiding in identifying new targets.

Conclusions:

• SCS technology is a powerful tool for dissecting TB pathogenesis and identifying novel diagnostic and therapeutic targets.
• Integrating SCS with immunotherapy research is crucial for developing more effective TB control strategies.
• Further research is needed to overcome challenges and fully leverage SCS for clinical applications in TB.